RenovoRx Inc reports results for the quarter ended June 30 - Earnings Summary
RenovoRx Inc reports results for the quarter ended June 30 - Earnings Summary
RenovoRx Inc RNXT.OQ reported a quarterly adjusted loss of 5 cents per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -8 cents. The mean expectation of four analysts for the quarter was for a loss of 7 cents per share. Wall Street expected results to range from -8 cents to -7 cents per share.
Revenue rose 115.4% to $909.00 thousand from a year ago; analysts expected $716.50 thousand.
RenovoRx Inc's reported EPS for the quarter was a loss of 6 cents.
The company reported a quarterly loss of $2.91 million.
RenovoRx Inc shares had risen by 17.3% this quarter and gained 36.9% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 3.3% in the last three months.
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
Wall Street's median 12-month price target for RenovoRx Inc is $5.50, about 79.6% above its last closing price of $1.12
This summary was machine generated from LSEG data August 12 at 10:25 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
Jun. 30 2026 | -0.07 | -0.05 | Beat |
Mar. 31 2026 | -0.08 | -0.09 | Missed |
Dec. 31 2025 | -0.08 | -0.08 | Met |
Sep. 30 2025 | -0.08 | -0.08 | Met |
Recent news on RenovoRx
See all newsBrief: Renovorx Advances Tamp Into Borderline Resectable Pancreatic Cancer With First Patient Enrolled In Investigator-Initiated Prism-Tamp Trial
RenovoRx Inc reports results for the quarter ended June 30 - Earnings Summary
Oncology device maker RenovoRx's Q2 revenue surges, raises FY outlook
Brief: RenovoRx Q2 Net Income USD -2.911 Million
Brief: Renovorx Achieves Major Milestone With Full Enrollment In Phase Iii Tiger-Pac Trial For Locally Advanced Pancreatic Cancer